Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
EMEA recommends withdrawal of the marketing authorisations for lumiracoxib-containing medicines
Notice type:
Advisory
Date:
14/12/2007
Product name or type:
Lumiracoxib-containing medicines-(Prexige)
Reference:
EMEA Press Release
Active Substance:
Lumiracoxib
Product Classification:
Non-steroidal anti-inflammatory drug (NSAID)- COX-2 inhibitors
Problem Or Issue:
Following review at EU level, withdrawal of marketing authorisations for all lumiracoxib-containing medicines has been recommended from Member States where the products are marketed (not available in Ireland), because of a risk of serious side effects affecting the liver. Lumiracoxib is a non-steroidal anti-inflammatory drug (NSAID) used for symptomatic relief in the treatment of osteoarthritis of the hip and knee.
Background Information Or Related Documents:
EMEA recommends withdrawal of the marketing authorisations for lumiracoxib-containing medicines Document
Further Information:
ForMedia enquiries only to: Martin Harvey Allchurch or Monika Benstetter Tel. (44-20) 74 18 84 27,
E-mail
press@emea.europa.eu
Media enquiries only to: Martin Harvey Allchurch or Monika Benstetter Tel. (44-20) 74 18 84 27,
E-mail
press@emea.europa.eu
For further information, click here to read the
Press Release
« Back
Date Printed: 27/07/2024